14 March 2025
EMA: First vaccine against epizootic haemorrhagic disease recommended for approval
The European Medicines Agency (EMA) has recommended the approval of Hepizovac, which is the first vaccine against epizootic haemorrhagic disease (EHD). It is authorised in the European Union for its use in cattle. The new vaccine is set to provide protection against the serotype 8 of the EHD virus (EDHV), which has been responsible for recent outbreaks in Europe.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting